Welch Group LLC Has $378,000 Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Welch Group LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 71.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 360 shares of the biopharmaceutical company’s stock after acquiring an additional 150 shares during the period. Welch Group LLC’s holdings in Regeneron Pharmaceuticals were worth $378,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of REGN. SteelPeak Wealth LLC raised its stake in shares of Regeneron Pharmaceuticals by 173.0% during the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $1,148,000 after buying an additional 692 shares during the last quarter. Atria Investments Inc raised its stake in shares of Regeneron Pharmaceuticals by 12.2% in the 1st quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock valued at $8,317,000 after purchasing an additional 941 shares during the period. Tri Locum Partners LP lifted its stake in Regeneron Pharmaceuticals by 104.5% in the 2nd quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock valued at $18,410,000 after acquiring an additional 8,949 shares in the last quarter. Nordea Investment Management AB boosted its holdings in Regeneron Pharmaceuticals by 23.2% during the first quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock worth $28,218,000 after purchasing an additional 5,495 shares during the last quarter. Finally, Tidal Investments LLC grew its holdings in shares of Regeneron Pharmaceuticals by 16.8% in the 1st quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock valued at $4,774,000 after acquiring an additional 711 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded up $4.75 during trading on Monday, hitting $937.77. 24,524 shares of the company’s stock were exchanged, compared to its average volume of 502,396. The company has a market cap of $103.38 billion, a PE ratio of 24.77, a P/E/G ratio of 3.20 and a beta of 0.12. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $772.84 and a fifty-two week high of $1,211.20. The stock’s 50 day moving average price is $1,088.44 and its two-hundred day moving average price is $1,041.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm’s revenue was up 12.3% on a year-over-year basis. During the same period in the previous year, the firm posted $8.79 EPS. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.6 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on REGN shares. StockNews.com raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 22nd. Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Morgan Stanley lowered their target price on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Finally, Wells Fargo & Company reduced their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $1,101.00.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the transaction, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now owns 4,204 shares of the company’s stock, valued at $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.